Analysis Of The Efficacy And Prognosis Of Combined Regimen And Sequential Regimen Of Anthracyclines And Taxanes In Neoadjuvant Chemotherapy For Breast Cancer

Background and Objective:Breast cancer,as one of the most common malignant tumors,has long troubled women’s health.In recent years,with the continuous progress of medical level,the diagnosis and treatment methods of breast cancer have been more and more abundant,and the clinical efficacy has been getting better and better.Neoadjuvant chemotherapy occupies an important position among many treatment methods.Pathologic complete response(p CR),as the main indicator for evaluating the efficacy of neoadjuvant chemotherapy,has been proposed by existing studies as an independent prognostic factor for the long-term survival of patients with breast cancer.The core medicines of neoadjuvant chemotherapy for breast cancer are anthracyclines and taxanes,but the compatibility of these two medicines for achieving the best effect is not clear.At present,there are currently two different clinical regimens for the compatibility of these two medicines,that is,combined regimen and sequential regimen of anthracyclines and taxanes.On this basis,the efficacy of these two regimens in neoadjuvant chemotherapy for breast cancer and their impact on the prognosis are specifically discussed in this paper.Method:In this paper,a retrospective analysis of 398 female patients with breast cancer treated in the Breast Diagnosis and Treatment Center of Qingdao University Hospital is carried out.The first admission of these patients is from January 2013 to December 2018.All patients are treated with both neoadjuvant chemotherapy regimens of anthracyclines and taxanes,and divided into two groups,namely the combined regimen group(291 cases)and the sequential regimen group(107 cases).The difference between the efficacy and prognosis of combined regimen and sequential regimen of anthracyclines and taxanes in neoadjuvant chemotherapy for breast cancer are observed,and the incidence of adverse reactions after treatment between the two groups are compared.Results :(1)Comparison of clinical efficacy between the combined regimen group and sequential regimen group: the objective response rate(ORR)and p CR rate of the combined regimen group are 84.2% and 18.9%,respectively,and the ORR and p CR rate of the sequential regimen group are 85.0% and 22.4%.There are no statistical differences in the ORR and p CR rate between the two groups(P>0.05).The 3-year disease-free survival rate was 74% in the anthracycl-taxus combination group,and 81% in the anthracycl-taxus sequential group,HR=1.463(0.885-2.418),P=0.138.The 3-year survival rate was 90% in anthracycline and taxus combination group,and 91% in anthracycline and taxus sequence group,HR=1.222(0.587-2.546),P=0.592.(2)Comparison of adverse reactions between the combined regimen and sequential regimen: the incidence of the combined regimen in leukocytopenia,hemoglobin reduction and liver damage was significantly higher than that in sequential regimen(P<0.05).It is found that thrombocytopenia occurred during the treatment of the two regimens,and the probability of occurrence is not statistically different(P>0.05).Conclusion:The analysis and evaluation of the efficacy and prognosis of combined regimen and sequential regimen of anthracyclines and taxanes during neoadjuvant chemotherapy for breast cancer can draw similar conclusions.However,the incidence of adverse reactions of the combined regimen is much higher than that of the sequential regimen,so we recommend that the sequential regimen be preferred.In addition,the results of this study also suggest that PCR can translate to better survival outcomes.